MedPath

Dopamine

Generic Name
Dopamine
Drug Type
Small Molecule
Chemical Formula
C8H11NO2
CAS Number
51-61-6
Unique Ingredient Identifier
VTD58H1Z2X
Background

One of the catecholamine neurotransmitters in the brain. It is derived from tyrosine and is the precursor to norepinephrine and epinephrine. Dopamine is a major transmitter in the extrapyramidal system of the brain, and important in regulating movement. A family of receptors (receptors, dopamine) mediate its action.

Indication

For the correction of hemodynamic imbalances present in the shock syndrome due to myocardial infarction, trauma, endotoxic septicemia, open-heart surgery, renal failure, and chronic cardiac decompensation as in congestive failure

Associated Conditions
Arrhythmia, Circulatory collapse and shock, Hypotension caused by Trauma, endotoxic septicemia, Open-heart Surgery, Renal Failure, chronic cardiac decompensation, Myocardial Infarction, Urine flow decreased caused by Trauma, endotoxic septicemia, Open-heart Surgery, Renal Failure, chronic cardiac decompensation, Myocardial Infarction, Decreased cardiac output caused by Trauma, endotoxic septicemia, Open-heart Surgery, Renal Failure, chronic cardiac decompensation, Myocardial Infarction
Clinical Trials
Related News

Cerevance's Solengepras Fails Primary Endpoint in Phase II Parkinson's Trial, Shows Promise for Non-Motor Symptoms

• Cerevance's GPR6 antagonist solengepras failed to meet its primary endpoint in the Phase II ASCEND trial as a monotherapy for early, untreated Parkinson's disease patients, showing only a small, non-significant improvement versus placebo. • Despite missing the primary endpoint, solengepras demonstrated promising trends in improving non-motor symptoms and functional impairments, with fewer adverse events related to non-motor symptoms reported in the treatment arm. • The company is advancing solengepras in the pivotal Phase III ARISE trial as an adjunctive therapy to levodopa for Parkinson's patients with motor fluctuations, with topline data expected in the first half of 2026.

Prasinezumab Phase IIb Trial Fails Primary Endpoint, Shows Promise in Parkinson's Subgroup

• Genentech's prasinezumab Phase IIb PADOVA study in early-stage Parkinson's missed its primary endpoint of delaying motor progression. • A pre-specified analysis showed a more pronounced effect in patients treated with levodopa (HR=0.79), suggesting a potential benefit in this subgroup. • The investigational monoclonal antibody continues to be well-tolerated, with ongoing open-label extension studies to further explore observed effects. • Roche plans to present full PADOVA study results at an upcoming medical meeting and will work with health authorities to determine next steps.

AASM Updates Restless Legs Syndrome Treatment Guidelines: Shifts Away from Dopamine Agonists

• The American Academy of Sleep Medicine has released new clinical guidelines for Restless Legs Syndrome treatment, emphasizing iron supplementation and alpha-2-delta ligands as primary interventions. • The 2024 guidelines mark a significant shift by recommending against standard use of dopamine agonists due to risk of symptom augmentation, representing a major change in RLS management approach. • New treatment recommendations include high-frequency bilateral peroneal nerve stimulation as a non-pharmacological option and specific protocols for special populations such as patients with end-stage renal disease.

FDA Approves PTC Therapeutics' Kebilidi, First Gene Therapy Dosed Directly into the Brain

• The FDA has approved Kebilidi (eladocagene exuparvovec), a gene therapy by PTC Therapeutics, for aromatic L-amino acid decarboxylase (AADC) deficiency, a rare genetic disorder. • Kebilidi is the first gene therapy approved in the U.S. that involves direct administration into the brain, offering a novel approach to treating AADC deficiency. • Clinical trials showed that Kebilidi led to significant improvements in gross motor function in pediatric patients, with earlier treatment associated with better outcomes. • The approval includes a priority review voucher for PTC Therapeutics, potentially accelerating the review of future rare disease drug candidates.

Parkinson's Disease Research Focuses on Disease-Modifying Therapies

• The Parkinson's disease (PD) therapeutic market faces unmet needs, notably the absence of neuroprotective/disease-modifying therapies (DMTs) and treatments for non-motor symptoms. • A significant portion of the PD drug development pipeline is dedicated to neuroprotective and disease-modifying agents, targeting mechanisms like alpha-synuclein aggregation and neuroinflammation. • Clinical trials are underway for therapies addressing postural instability, PD-dementia, and cognitive/emotional impairments, reflecting a comprehensive approach to managing PD's complexities.

Vimgreen Completes Enrollment in Phase 2 Trial of VG081821AC for Parkinson's Disease

• Vimgreen Pharmaceuticals has completed enrollment of 150 participants in a Phase 2 trial of VG081821AC for early-to-mid stage Parkinson's disease. • The trial is a 12-week, multicenter, randomized, double-blind, placebo-controlled study evaluating VG081821AC as a monotherapy. • VG081821AC, a novel adenosine A2A receptor antagonist and inverse agonist, aims to improve motor symptoms and potentially modify disease progression. • The primary endpoint is the change from baseline in MDS-UPDRS Part III score, with trial completion expected in November.
© Copyright 2025. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy